Informatique de santé - Identification des médicaments - Éléments de données et structures pour l'identification unique et l'échange d'informations sur les médicaments contrôlés
Introduction: This document was developed in response to a worldwide demand for internationally harmonised specifications for Medicinal Products. It is part of a set of five ISO Standards and four ISO Technical Specifications which together provide the basis for the unique Identification of Medicinal Products (IDMP). These sets of standards and technical specifications comprise: — ISO 11615 — ISO/TS 20443; — ISO 11616; — ISO/TS 20451; — ISO 11238; — ISO/TS 19844; — ISO 11239; — ISO/TS 20440; — ISO 11240. These standards and technical specifications for the identification of Medicinal Products (IDMP) support the activities of medicines regulatory agencies worldwide by region. These include a variety of regulatory activities related to development, registration and life cycle management of Medicinal Products, as well as pharmacovigilance and risk management. To meet the primary objectives of the regulation of medicines and pharmacovigilance, it is necessary to reliably exchange Medicinal Product information in a robust and consistent manner. The IDMP standards therefore support, at a minimum, the following interactions: — regulatory medicines authority to regulatory medicines authority; — pharmaceutical company to regulatory medicines authority; — sponsor of a clinical trial to regulatory medicines authority; — regulatory medicines authority to other stakeholders (as applicable); — regulatory medicines authority to worldwide-maintained data sources. The necessary messaging specifications are
Scope: This document establishes definitions and concepts and describes data elements and their structural relationships, which are required for the unique identification and the detailed description of Medicinal Products. Taken together, the standards listed in the Introduction define, characterise and uniquely identify regulated Medicinal Products for human use during their entire life cycle, i.e. from development to authorisation, post-marketing and renewal or withdrawal from the market, where applicable. Furthermore, to support successful information exchange in relation to the unique identification and characterisation of Medicinal Products, the use of other normative IDMP messaging standards is included, which are to be applied in the context of this document.